Antibody-drug conjugates (ADCs): all 1,111 studies that test it
Page 12 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.
- Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell TransplantCompletedNCT00044733Phase 2
- Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDSCompletedNCT00038831Phase 1/2
- Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)TerminatedNCT00038805Phase 2/3
- Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid LeukemiaCompletedNCT00037596Phase 2
- Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid LeukemiaCompletedNCT00037583Phase 2
- Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00028899Phase 1
- Gemtuzumab in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT00022321Phase 2
- Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00017589Phase 2
- Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00008151Phase 2
- Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00006265Phase 2
- Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00006122Phase 2